Novartis Opens Pharmaceutical Plant In Singapore, Biotech Plant to Come

Article

Novartis (Basel, Switzerland) officially opened a new pharmaceutical manufacturing site in Tuas, Singapore on October 29, 2007, adding capacity to its global production network to meet business growth and support new product launches in the US and Japanese markets.

Novartis (Basel, Switzerland) officially opened a new pharmaceutical manufacturing site in Tuas, Singapore on October 29, 2007, adding capacity to its global production network to meet business growth and support new product launches in the US and Japanese markets.

The plant will manufacture solid dosage forms of existing Novartis pharmaceutical brands, such as Diovan, and new products, like Tekturna. It is expected to be fully operational in 2009 and will employ approximately 160 employees.

Novartis also unveiled its plan to build a large-scale biotechnology plant in Singapore to support the rapid growth of its biologics sector, which now accounts for 25 percent of the Novartis product pipeline. Novartis expects to invest approximately $700 million-its largest investment to date in manufacturing capacity-in the new, state-of-the-art cell-culture facility.

Construction on the new biotech plant is expected to start in early 2008, and it will employ more than 300 people when fully operational by the end of 2012, subject to regulatory approvals. The cell-culture plant will support both clinical and commercial production of potential new products in the area of biopharmaceutical therapies, primarily monoclonal antibodies.

Singapore Economic Development Board release

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Mike Schaefers Simtra BioPharma Solutions, Shiva Khalafpour MilliporeSigma, the Life Science Business of Merck KGaA, Darmstadt, Germany
Chris Hagen, SCIEX
Daniel Fischer, Tevard
Related Content
© 2025 MJH Life Sciences

All rights reserved.